HLA-DQB1	B-DNA
codon	I-DNA
57	I-DNA
is	O
critical	O
for	O
peptide	O
binding	O
and	O
recognition	O
.	O

The	O
association	O
of	O
specific	O
HLA-DQ	B-DNA
alleles	I-DNA
with	O
autoimmunity	O
is	O
correlated	O
with	O
discrete	O
polymorphisms	O
in	O
the	O
HLA-DQ	B-DNA
sequence	I-DNA
that	O
are	O
localized	O
within	O
sites	O
suitable	O
for	O
peptide	O
recognition	O
.	O

The	O
polymorphism	O
at	O
residue	O
57	O
of	O
the	O
DQB1	O
polypeptide	O
is	O
of	O
particular	O
interest	O
since	O
it	O
may	O
play	O
a	O
major	O
structural	O
role	O
in	O
the	O
formation	O
of	O
a	O
salt	B-protein
bridge	I-protein
structure	I-protein
at	O
one	O
end	O
of	O
the	O
peptide-binding	B-protein
cleft	I-protein
of	O
the	O
DQ	O
molecules	O
.	O

This	O
polymorphism	O
at	O
residue	O
57	O
is	O
a	O
recurrent	O
feature	O
of	O
HLA-DQ	O
evolution	O
,	O
occurring	O
in	O
multiple	O
distinct	O
allelic	O
families	O
,	O
which	O
implies	O
a	O
functional	O
selection	O
for	O
maintaining	O
variation	O
at	O
this	O
position	O
in	O
the	O
class	B-protein
II	I-protein
molecule	I-protein
.	O

We	O
directly	O
tested	O
the	O
amino	O
acid	O
polymorphism	O
at	O
this	O
site	O
as	O
a	O
determinant	O
for	O
peptide	O
binding	O
and	O
for	O
antigen-specific	O
T	O
cell	O
stimulation	O
.	O

We	O
found	O
that	O
a	O
single	O
Ala	O
--	O
>	O
Asp	O
amino	O
acid	O
57	O
substitution	O
in	O
an	O
HLA-DQ3.2	O
molecule	O
regulated	O
binding	O
of	O
an	O
HSV-2	O
VP-16-derived	O
peptide	O
.	O

A	O
complementary	O
single-residue	O
substitution	O
in	O
the	O
peptide	O
abolished	O
its	O
binding	O
to	O
DQ3.2	O
and	O
converted	O
it	O
to	O
a	O
peptide	O
that	O
can	O
bind	O
to	O
DQ3.1	O
and	O
DQ3.3	B-protein
Asp-57-positive	I-protein
MHC	I-protein
molecules	I-protein
.	O

These	O
binding	O
studies	O
were	O
paralleled	O
by	O
specific	O
T	O
cell	O
recognition	O
of	O
the	O
class	B-protein
II-peptide	I-protein
complex	I-protein
,	O
in	O
which	O
the	O
substituted	O
peptide	O
abolished	O
T	O
cell	O
reactivity	O
,	O
which	O
was	O
directed	O
to	O
the	O
DQ3.2-peptide	B-protein
complex	I-protein
,	O
whereas	O
the	O
same	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
recognized	O
the	O
substituted	O
peptide	O
presented	O
by	O
DQ3.3	O
,	O
a	O
class	O
II	O
restriction	O
element	O
differing	O
from	O
DQ3.2	O
only	O
at	O
residue	O
57	O
.	O

This	O
structural	O
and	O
functional	O
complementarity	O
for	O
residue	O
57	O
and	O
a	O
specific	O
peptide	O
residue	O
identifies	O
this	O
interaction	O
as	O
a	O
key	O
controlling	O
determinant	O
of	O
restricted	O
recognition	O
in	O
HLA-DQ-specific	O
immune	O
response	O
.	O

Brief	NULL
Definitive	NULL
Report	NULL
HLA-DQB1	NULL
Codon	NULL
57	NULL
Is	NULL
Critical	NULL
for	NULL
Peptide	NULL
Binding	NULL
and	NULL
Recognition	NULL
By	NULL
W.W.	NULL
Kwok	NULL
,	NULL
*	NULL
M.E	NULL
.	NULL

Domeier	NULL
,	NULL
*	NULL
ML	NULL
.	NULL

Johnson	NULL
,	NULL
t	NULL
G.T	NULL
.	NULL

Nepom	NULL
,	NULL
**	NULL
and	NULL
D.M	NULL
.	NULL

Koellet	NULL
From	NULL
the	NULL
*	NULL
Virginia	NULL
Mason	NULL
Research	NULL
Center	NULL
and	NULL
the	NULL
*University	NULL
of	NULL
Washington	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Seattle	NULL
,	NULL
Washington	NULL
98101	NULL
Summary	NULL
The	NULL
association	NULL
of	NULL
specific	NULL
HLA-DQ	NULL
alleles	NULL
with	NULL
autoimmunity	NULL
is	NULL
correlated	NULL
with	NULL
discrete	NULL
polymorphisms	NULL
in	NULL
the	NULL
HLA-DQ	NULL
sequence	NULL
that	NULL
are	NULL
localized	NULL
within	NULL
sites	NULL
suitable	NULL
for	NULL
peptide	NULL
recognition	NULL
.	NULL

The	NULL
polymorphism	NULL
at	NULL
residue	NULL
57	NULL
of	NULL
the	NULL
DQB1	NULL
polypeptide	NULL
is	NULL
of	NULL
particular	NULL
interest	NULL
since	NULL
it	NULL
may	NULL
play	NULL
a	NULL
major	NULL
structural	NULL
role	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
salt	NULL
bridge	NULL
structure	NULL
at	NULL
one	NULL
end	NULL
of	NULL
the	NULL
peptide-binding	NULL
cleft	NULL
of	NULL
the	NULL
DQ	NULL
molecules	NULL
.	NULL

This	NULL
polymorphism	NULL
at	NULL
residue	NULL
57	NULL
is	NULL
a	NULL
recurrent	NULL
feature	NULL
of	NULL
HLA-DQ	NULL
evolution	NULL
,	NULL
occurring	NULL
in	NULL
multiple	NULL
distinct	NULL
allelic	NULL
families	NULL
,	NULL
which	NULL
implies	NULL
a	NULL
functional	NULL
selection	NULL
for	NULL
maintaining	NULL
variation	NULL
at	NULL
this	NULL
position	NULL
in	NULL
the	NULL
class	NULL
II	NULL
molecule	NULL
.	NULL

We	NULL
directly	NULL
tested	NULL
the	NULL
amino	NULL
acid	NULL
polymorphism	NULL
at	NULL
this	NULL
site	NULL
as	NULL
a	NULL
determinant	NULL
for	NULL
peptide	NULL
binding	NULL
and	NULL
for	NULL
an-tigen-specific	NULL
T	NULL
cell	NULL
stimulation	NULL
.	NULL

We	NULL
found	NULL
that	NULL
a	NULL
single	NULL
Ala-	NULL
>	NULL
Asp	NULL
amino	NULL
acid	NULL
57	NULL
substitution	NULL
in	NULL
an	NULL
HLA-DQ3.2	NULL
molecule	NULL
regulated	NULL
binding	NULL
of	NULL
an	NULL
HSV-2	NULL
VP-16-derived	NULL
peptide	NULL
.	NULL

A	NULL
complementary	NULL
single-residue	NULL
substitution	NULL
in	NULL
the	NULL
peptide	NULL
abolished	NULL
its	NULL
binding	NULL
to	NULL
DQ3.2	NULL
and	NULL
converted	NULL
it	NULL
to	NULL
a	NULL
peptide	NULL
that	NULL
can	NULL
bind	NULL
to	NULL
DQ3.1	NULL
and	NULL
DQ3.3	NULL
Asp-57-positive	NULL
MHC	NULL
molecules	NULL
.	NULL

These	NULL
binding	NULL
studies	NULL
were	NULL
paralleled	NULL
by	NULL
specific	NULL
T	NULL
cell	NULL
recognition	NULL
of	NULL
the	NULL
class	NULL
II-peptide	NULL
complex	NULL
,	NULL
in	NULL
which	NULL
the	NULL
substituted	NULL
peptide	NULL
abolished	NULL
T	NULL
cell	NULL
reactivity	NULL
,	NULL
which	NULL
was	NULL
directed	NULL
to	NULL
the	NULL
DQ3.2-peptide	NULL
complex	NULL
,	NULL
whereas	NULL
the	NULL
same	NULL
T	NULL
cell	NULL
clone	NULL
recognized	NULL
the	NULL
substituted	NULL
peptide	NULL
presented	NULL
by	NULL
DQ3.3	NULL
,	NULL
a	NULL
class	NULL
II	NULL
restriction	NULL
element	NULL
differing	NULL
from	NULL
DQ3.2	NULL
only	NULL
at	NULL
residue	NULL
57	NULL
.	NULL

This	NULL
structural	NULL
and	NULL
functional	NULL
complementarity	NULL
for	NULL
residue	NULL
57	NULL
and	NULL
a	NULL
specific	NULL
peptide	NULL
residue	NULL
identifies	NULL
this	NULL
interaction	NULL
as	NULL
a	NULL
key	NULL
controlling	NULL
determinant	NULL
of	NULL
restricted	NULL
recognition	NULL
in	NULL
HLA-DQ-specific	NULL
im-	NULL
mune	NULL
responses	NULL
.	NULL

HC	NULL
class	NULL
II	NULL
proteins	NULL
act	NULL
as	NULL
peptide-binding	NULL
molecules	NULL
for	NULL
presenting	NULL
antigenic	NULL
peptides	NULL
to	NULL
T	NULL
cells	NULL
.	NULL

Both	NULL
peptide	NULL
sequence-specific	NULL
and	NULL
peptide	NULL
sequence-nonspecific	NULL
interactions	NULL
with	NULL
the	NULL
MHC	NULL
molecules	NULL
contribute	NULL
to	NULL
the	NULL
stabilization	NULL
of	NULL
the	NULL
MHC-peptide	NULL
complex	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

Interactions	NULL
of	NULL
peptide	NULL
main-chain	NULL
carbonyl	NULL
and	NULL
amide	NULL
groups	NULL
with	NULL
MHC	NULL
residues	NULL
by	NULL
hydrogen	NULL
bond	NULL
and	NULL
Van	NULL
der	NULL
Waals	NULL
force	NULL
provide	NULL
the	NULL
free	NULL
energy	NULL
for	NULL
sequence-nonspecific	NULL
binding	NULL
.	NULL

Interactions	NULL
of	NULL
peptide	NULL
side	NULL
chains	NULL
with	NULL
polymorphic	NULL
residues	NULL
within	NULL
the	NULL
binding	NULL
pockets	NULL
of	NULL
the	NULL
MHC	NULL
impose	NULL
peptide-binding	NULL
specificity	NULL
,	NULL
which	NULL
varies	NULL
for	NULL
different	NULL
MHC	NULL
molecules	NULL
.	NULL

X-ray	NULL
crystallography	NULL
of	NULL
one	NULL
of	NULL
these	NULL
MHC	NULL
molecules	NULL
,	NULL
HLA-DR	NULL
1	NULL
,	NULL
indicated	NULL
there	NULL
are	NULL
four	NULL
major	NULL
binding	NULL
pockets	NULL
in	NULL
the	NULL
DR1	NULL
molecules	NULL
,	NULL
termed	NULL
pockets	NULL
1	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
9	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
,	NULL
which	NULL
accommodate	NULL
specific	NULL
anchor	NULL
residues	NULL
from	NULL
the	NULL
peptide	NULL
.	NULL

Much	NULL
of	NULL
the	NULL
sequence	NULL
polymorphism	NULL
among	NULL
HLA-DR	NULL
alleles	NULL
clusters	NULL
in	NULL
these	NULL
pockets	NULL
,	NULL
providing	NULL
the	NULL
structural	NULL
basis	NULL
by	NULL
which	NULL
different	NULL
molecules	NULL
bind	NULL
and	NULL
present	NULL
different	NULL
antigens	NULL
.	NULL

Preferential	NULL
interactions	NULL
between	NULL
polymorphic	NULL
pockets	NULL
and	NULL
specific	NULL
anchor	NULL
residues	NULL
create	NULL
peptide	NULL
``	NULL
mo-tifs	NULL
``	NULL
in	NULL
which	NULL
the	NULL
pattern	NULL
of	NULL
residues	NULL
within	NULL
a	NULL
peptide	NULL
sequence	NULL
dictates	NULL
its	NULL
preferential	NULL
MHC	NULL
binding	NULL
partner	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

1253	NULL
In	NULL
contrast	NULL
to	NULL
HLA-DR	NULL
,	NULL
binding	NULL
motifs	NULL
for	NULL
HLA-DQ	NULL
molecules	NULL
remain	NULL
largely	NULL
unknown	NULL
(	NULL
8-10	NULL
)	NULL
,	NULL
although	NULL
polymorphisms	NULL
in	NULL
binding	NULL
pockets	NULL
that	NULL
distinguish	NULL
among	NULL
DQ	NULL
molecules	NULL
are	NULL
associated	NULL
with	NULL
several	NULL
autoimmune	NULL
diseases	NULL
,	NULL
including	NULL
type	NULL
1	NULL
diabetes	NULL
mellitus	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
the	NULL
HLA-DQ3.2	NULL
molecule	NULL
,	NULL
highly	NULL
associated	NULL
with	NULL
disease	NULL
,	NULL
is	NULL
highly	NULL
homologous	NULL
to	NULL
two	NULL
naturally	NULL
occurring	NULL
alleles	NULL
,	NULL
HLA-DQ3.1	NULL
and	NULL
HLA-DQ3.3	NULL
.	NULL

These	NULL
three	NULL
DQ	NULL
molecules	NULL
have	NULL
identical	NULL
DQa	NULL
chains	NULL
(	NULL
DQA1*0301	NULL
)	NULL
and	NULL
DQB	NULL
chains	NULL
with	NULL
extremely	NULL
high	NULL
amino	NULL
acid	NULL
sequence	NULL
similarity	NULL
;	NULL
the	NULL
DQ3.2	NULL
and	NULL
DQ3.3	NULL
B	NULL
alleles	NULL
(	NULL
DQB1*0302	NULL
and	NULL
DQB1*0303	NULL
,	NULL
re-spectively	NULL
)	NULL
differ	NULL
only	NULL
in	NULL
an	NULL
Ala-	NULL
>	NULL
Asp	NULL
polymorphism	NULL
at	NULL
codon	NULL
57	NULL
,	NULL
whereas	NULL
the	NULL
DQ3.1fB	NULL
allele	NULL
(	NULL
DQB1*0301	NULL
)	NULL
encodes	NULL
Asp	NULL
57	NULL
and	NULL
three	NULL
additional	NULL
polymorphisms	NULL
at	NULL
positions	NULL
13	NULL
,	NULL
26	NULL
,	NULL
and	NULL
45	NULL
.	NULL

The	NULL
aspartic	NULL
residue	NULL
in	NULL
DQ3.1	NULL
and	NULL
DQ3.3	NULL
likely	NULL
interacts	NULL
with	NULL
an	NULL
arginine	NULL
at	NULL
residue	NULL
79	NULL
of	NULL
the	NULL
DQA1	NULL
chain	NULL
to	NULL
form	NULL
a	NULL
salt	NULL
bridge	NULL
by	NULL
analogy	NULL
with	NULL
a	NULL
similar	NULL
structure	NULL
in	NULL
HLA-DR1	NULL
(	NULL
3	NULL
)	NULL
,	NULL
whereas	NULL
DQ3.2	NULL
lacks	NULL
this	NULL
interac-tion	NULL
.	NULL

An	NULL
influence	NULL
of	NULL
this	NULL
potential	NULL
salt	NULL
bridge	NULL
in	NULL
DQ	NULL
on	NULL
peptide	NULL
binding	NULL
has	NULL
been	NULL
suggested	NULL
(	NULL
13	NULL
)	NULL
but	NULL
not	NULL
yet	NULL
directly	NULL
tested	NULL
.	NULL

We	NULL
have	NULL
analyzed	NULL
these	NULL
three	NULL
different	NULL
DQ	NULL
alleles	NULL
to	NULL
examine	NULL
peptide-binding	NULL
specificity	NULL
to	NULL
DQ	NULL
molecules	NULL
in	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

©	NULL
The	NULL
Rockefeller	NULL
University	NULL
Press	NULL
«	NULL
0022-1007/96/03/1253/06	NULL
$	NULL
2.00	NULL
Volume	NULL
183	NULL
March	NULL
1996	NULL
1253-1258	NULL
fluenced	NULL
by	NULL
the	NULL
codon	NULL
57	NULL
polymorphism	NULL
.	NULL

A	NULL
peptide-spe-cific	NULL
,	NULL
DQ3.2-restricted	NULL
T	NULL
cell	NULL
clone	NULL
was	NULL
also	NULL
used	NULL
to	NULL
assess	NULL
the	NULL
functional	NULL
consequences	NULL
of	NULL
modulating	NULL
peptide	NULL
binding	NULL
on	NULL
TCR	NULL
interaction	NULL
with	NULL
the	NULL
DQ-peptide	NULL
complex	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cell	NULL
Lines	NULL
.	NULL

-	NULL
EBV-transformed	NULL
B	NULL
cell	NULL
lines	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
X	NULL
International	NULL
Histocompatibility	NULL
Workshop	NULL
.	NULL

The	NULL
VP16-restricted	NULL
T	NULL
cell	NULL
clone	NULL
2A.334	NULL
was	NULL
derived	NULL
from	NULL
the	NULL
HSV-2	NULL
lesion	NULL
of	NULL
a	NULL
patient	NULL
(	NULL
HLA	NULL
DQA1*0301/DQB1*0302	NULL
,	NULL
DQA1*0103/	NULL
DQB1*0603	NULL
)	NULL
with	NULL
herpetic	NULL
vesicles	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
from	NULL
herpetic	NULL
vesicles	NULL
were	NULL
centrifuged	NULL
through	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
;	NULL
10°	NULL
cells	NULL
were	NULL
stimulated	NULL
in	NULL
bulk	NULL
with	NULL
1.5	NULL
X	NULL
105	NULL
allogeneic	NULL
irradiated	NULL
PBMC	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inacti-vated	NULL
pooled	NULL
human	NULL
serum	NULL
,	NULL
1	NULL
%	NULL
penicillin-streptomycin	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
PHA	NULL
(	NULL
0.4	NULL
pg/m	NULL
!	NULL

l	NULL
)	NULL
,	NULL
and	NULL
human	NULL
IL-2	NULL
(	NULL
50	NULL
U/ml	NULL
;	NULL
Schi-aperelli	NULL
Biosystems	NULL
,	NULL
Fairfield	NULL
,	NULL
NJ	NULL
)	NULL
(	NULL
14	NULL
)	NULL
.	NULL

After	NULL
16	NULL
d	NULL
of	NULL
growth	NULL
,	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
restimulated	NULL
with	NULL
HSV-2	NULL
antigen	NULL
and	NULL
5	NULL
X	NULL
10°	NULL
autologous	NULL
irradiated	NULL
PBMC	NULL
in	NULL
1-ml	NULL
cultures	NULL
,	NULL
and	NULL
10-12	NULL
d	NULL
later	NULL
they	NULL
were	NULL
cloned	NULL
at	NULL
1	NULL
cell/well	NULL
using	NULL
PHA	NULL
,	NULL
IL-2	NULL
,	NULL
and	NULL
allogeneic	NULL
feeder	NULL
cells	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Clones	NULL
judged	NULL
to	NULL
have	NULL
HSV-2	NULL
type-specific	NULL
responses	NULL
(	NULL
stimulation	NULL
index	NULL
with	NULL
HSV-2	NULL
antigen	NULL
>	NULL
4.0	NULL
and	NULL
no	NULL
specific	NULL
stimulation	NULL
with	NULL
HSV-1	NULL
antigen	NULL
)	NULL
were	NULL
screened	NULL
for	NULL
reactivity	NULL
with	NULL
HSV-1	NULL
X	NULL
HSV-2	NULL
intertypic	NULL
recombinant	NULL
virus	NULL
RP-2	NULL
.	NULL

HSV-2	NULL
type-specific	NULL
T	NULL
cell	NULL
clones	NULL
reactive	NULL
with	NULL
RP-2	NULL
are	NULL
specific	NULL
for	NULL
VP16	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Peptide-binding	NULL
Assays	NULL
.	NULL

10°	NULL
EBV-transformed	NULL
human	NULL
B	NULL
cells	NULL
(	NULL
PRIESS	NULL
,	NULL
DQ3.2	NULL
;	NULL
PF	NULL
,	NULL
DQ3.1	NULL
;	NULL
HID	NULL
,	NULL
DQ3.3	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
0.5	NULL
%	NULL
paraformaldehyde	NULL
for	NULL
10	NULL
min	NULL
and	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
HBSS	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
resuspended	NULL
with	NULL
10	NULL
jwM	NULL
biotinylated	NULL
peptide	NULL
in	NULL
150	NULL
mM	NULL
citrate-phosphate	NULL
buffer	NULL
,	NULL
pH	NULL
4.4	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
in	NULL
a	NULL
100	NULL
pl	NULL
reaction	NULL
volume	NULL
for	NULL
24	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
HBSS	NULL
before	NULL
lysis	NULL
in	NULL
100	NULL
ul	NULL
buffer	NULL
containing	NULL
0.5	NULL
%	NULL
NP-40	NULL
,	NULL
0.15	NULL
M	NULL
NaCl	NULL
,	NULL
50	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
and	NULL
protease	NULL
inhibitors	NULL
.	NULL

The	NULL
lysates	NULL
were	NULL
cleared	NULL
by	NULL
centrifugation	NULL
,	NULL
and	NULL
then	NULL
transferred	NULL
to	NULL
96-well	NULL
plates	NULL
precoated	NULL
with	NULL
10	NULL
ug/ml	NULL
mAb	NULL
SPVL3	NULL
(	NULL
specific	NULL
for	NULL
HLA-DQ	NULL
)	NULL
and	NULL
blocked	NULL
with	NULL
5	NULL
%	NULL
FCS	NULL
in	NULL
PBS	NULL
.	NULL

The	NULL
lysate	NULL
was	NULL
neutralized	NULL
with	NULL
100	NULL
pl	NULL
of	NULL
50	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
containing	NULL
0.02	NULL
%	NULL
n-dodecyl	NULL
B-p-maitoside	NULL
and	NULL
incubated	NULL
overnight	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
wells	NULL
were	NULL
then	NULL
washed	NULL
with	NULL
PBS	NULL
containing	NULL
0.02	NULL
%	NULL
Tween	NULL
20	NULL
.	NULL

Europium-labeled	NULL
streptavidin	NULL
(	NULL
Wallac	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
was	NULL
added	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
200	NULL
pl	NULL
DELFIA	NULL
assay	NULL
buffer	NULL
(	NULL
Wallac	NULL
)	NULL
and	NULL
incubated	NULL
at	NULL
4°C	NULL
for	NULL
4	NULL
h.	NULL
After	NULL
washing	NULL
,	NULL
200	NULL
pl	NULL
of	NULL
enhancement	NULL
buffer	NULL
(	NULL
Wallac	NULL
)	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
resultant	NULL
fluorescence	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
DELFIA	NULL
1232	NULL
fluorometer	NULL
.	NULL

Peptides	NULL
were	NULL
provided	NULL
by	NULL
Drs	NULL
.	NULL

R.	NULL
Burke	NULL
and	NULL
M.	NULL
Tigges	NULL
(	NULL
Chiron	NULL
Corp.	NULL
,	NULL
Emeryville	NULL
,	NULL
CA	NULL
)	NULL
or	NULL
synthesized	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Cytotoxic	NULL
T	NULL
Cell	NULL
Assays	NULL
.	NULL

10°	NULL
target	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
125	NULL
Ci	NULL
``	NULL
Cr	NULL
and	NULL
0.005-5	NULL
pg/ml	NULL
of	NULL
peptide	NULL
for	NULL
90	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
and	NULL
plated	NULL
at	NULL
3	NULL
X	NULL
10°	NULL
cells/wells	NULL
into	NULL
96-well	NULL
U-bottom	NULL
plates	NULL
.	NULL

Cloned	NULL
T	NULL
cells	NULL
were	NULL
added	NULL
at	NULL
an	NULL
E/T	NULL
ratio	NULL
of	NULL
20:1	NULL
,	NULL
with	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
200	NULL
pul/well	NULL
with	NULL
or	NULL
without	NULL
10	NULL
pug/	NULL
ml	NULL
mAb	NULL
SPV	NULL
L3	NULL
or	NULL
L243	NULL
(	NULL
specific	NULL
for	NULL
HLA-DR	NULL
)	NULL
.	NULL

After	NULL
4	NULL
h	NULL
at	NULL
37°C	NULL
,	NULL
30	NULL
pul	NULL
of	NULL
supernatant	NULL
was	NULL
counted	NULL
using	NULL
a	NULL
scintillation	NULL
counter	NULL
(	NULL
Lumaplates	NULL
and	NULL
Topcount	NULL
;	NULL
Packard	NULL
,	NULL
Meriden	NULL
,	NULL
CT	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
reported	NULL
as	NULL
percentage	NULL
of	NULL
specific	NULL
lysis	NULL
,	NULL
defined	NULL
as	NULL
[	NULL
mean	NULL
experimental	NULL
cpm	NULL
-	NULL
mean	NULL
spontaneous	NULL
cpm	NULL
)	NULL
/	NULL
(	NULL
mean	NULL
maximum	NULL
cpm	NULL
mean	NULL
spontaneous	NULL
cpm	NULL
)	NULL
]	NULL
X	NULL
100	NULL
.	NULL

Assays	NULL
were	NULL
performed	NULL
in	NULL
tripli-cate	NULL
,	NULL
and	NULL
spontaneous	NULL
release	NULL
was	NULL
usually	NULL
<	NULL
30	NULL
%	NULL
of	NULL
total	NULL
release	NULL
.	NULL

Proliferation	NULL
Assays	NULL
.	NULL

T	NULL
cells	NULL
(	NULL
10*/well	NULL
)	NULL
and	NULL
autologous	NULL
irradiated	NULL
PBMC	NULL
(	NULL
105/well	NULL
)	NULL
as	NULL
APC	NULL
were	NULL
added	NULL
to	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
1254	NULL
200	NULL
ul	NULL
of	NULL
T	NULL
cell	NULL
medium	NULL
in	NULL
96-well	NULL
U-bottom	NULL
plates	NULL
.	NULL

Peptide	NULL
was	NULL
used	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
5	NULL
ug/ml	NULL
.	NULL

After	NULL
3	NULL
d	NULL
,	NULL
[	NULL
}	NULL
HJthymi-dine	NULL
(	NULL
1	NULL
pCi/well	NULL
)	NULL
was	NULL
added	NULL
for	NULL
18	NULL
h	NULL
;	NULL
cells	NULL
were	NULL
harvested	NULL
with	NULL
a	NULL
semiautomatic	NULL
harvester	NULL
and	NULL
counted	NULL
by	NULL
liquid	NULL
scintillation	NULL
.	NULL

Stimulation	NULL
index	NULL
is	NULL
defined	NULL
as	NULL
mean	NULL
cpm	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
for	NULL
antigen/mean	NULL
cpm	NULL
of	NULL
[	NULL
*H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
for	NULL
control	NULL
antigen	NULL
.	NULL

Results	NULL
and	NULL
Discussion	NULL
The	NULL
T	NULL
cell	NULL
clone	NULL
24.334	NULL
,	NULL
reactive	NULL
with	NULL
VP16	NULL
,	NULL
was	NULL
identified	NULL
by	NULL
screening	NULL
HSV-2	NULL
type-specific	NULL
clones	NULL
with	NULL
a	NULL
panel	NULL
of	NULL
HSV-1	NULL
and	NULL
HSV-2	NULL
intertypic	NULL
recombinant	NULL
viruses	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
CD4*	NULL
T	NULL
cell	NULL
clone	NULL
2A.334	NULL
was	NULL
defined	NULL
using	NULL
a	NULL
set	NULL
of	NULL
overlapping	NULL
peptides	NULL
corresponding	NULL
to	NULL
amino	NULL
acids	NULL
410-469	NULL
of	NULL
VP16	NULL
of	NULL
HSV-2	NULL
,	NULL
the	NULL
region	NULL
of	NULL
maximum	NULL
sequence	NULL
divergence	NULL
between	NULL
HSV-2	NULL
and	NULL
HSV-1	NULL
.	NULL

Initial	NULL
screening	NULL
by	NULL
proliferation	NULL
assay	NULL
using	NULL
overlapping	NULL
15-mer	NULL
peptides	NULL
identified	NULL
reactivity	NULL
to	NULL
VP16	NULL
430-444	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
4	NULL
)	NULL
.	NULL

Subsequent	NULL
analysis	NULL
of	NULL
cytolytic	NULL
activity	NULL
using	NULL
13-mers	NULL
derived	NULL
from	NULL
this	NULL
sequence	NULL
demonstrated	NULL
reactivity	NULL
with	NULL
433-445	NULL
,	NULL
but	NULL
not	NULL
429-441	NULL
,	NULL
defining	NULL
an	NULL
epitope	NULL
included	NULL
within	NULL
the	NULL
sequence	NULL
DMTPADALDDFDL	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

1	NULL
C	NULL
summarizes	NULL
the	NULL
restriction	NULL
pattern	NULL
of	NULL
this	NULL
clone	NULL
,	NULL
which	NULL
recognized	NULL
the	NULL
VP16	NULL
433-445	NULL
peptide	NULL
of	NULL
HSV-2	NULL
presented	NULL
by	NULL
DQA1*0301/DQB1*0302	NULL
;	NULL
the	NULL
cytolytic	NULL
activity	NULL
of	NULL
the	NULL
clone	NULL
was	NULL
inhibited	NULL
by	NULL
the	NULL
anti-DQ	NULL
mAb	NULL
SPVL3	NULL
but	NULL
not	NULL
by	NULL
the	NULL
anti-DR	NULL
mAb	NULL
L243	NULL
.	NULL

Since	NULL
neither	NULL
DQB1*0301	NULL
nor	NULL
DQB1*	NULL
0303	NULL
presented	NULL
the	NULL
HSV-2	NULL
peptide	NULL
to	NULL
clone	NULL
2A.334	NULL
,	NULL
we	NULL
tested	NULL
these	NULL
alleles	NULL
in	NULL
peptide-binding	NULL
assays	NULL
with	NULL
peptide	NULL
433-445	NULL
.	NULL

Fig	NULL
.	NULL

2	NULL
A	NULL
shows	NULL
that	NULL
the	NULL
peptide	NULL
bound	NULL
DQBI1*	NULL
0302	NULL
,	NULL
but	NULL
not	NULL
DQB1*0301	NULL
nor	NULL
``	NULL
0303	NULL
.	NULL

Since	NULL
the	NULL
DQ3.3	NULL
molecule	NULL
differs	NULL
from	NULL
DQ3.2	NULL
only	NULL
in	NULL
an	NULL
Ala-	NULL
>	NULL
Asp	NULL
57	NULL
poly-morphism	NULL
,	NULL
this	NULL
directly	NULL
correlates	NULL
variation	NULL
at	NULL
this	NULL
residue	NULL
with	NULL
altered	NULL
peptide	NULL
binding	NULL
.	NULL

To	NULL
determine	NULL
which	NULL
residues	NULL
on	NULL
the	NULL
HSV-2	NULL
peptide	NULL
likely	NULL
interact	NULL
with	NULL
the	NULL
codon	NULL
57	NULL
residue	NULL
,	NULL
we	NULL
synthesized	NULL
modified	NULL
HSV-2	NULL
peptides	NULL
that	NULL
reconstituted	NULL
binding	NULL
to	NULL
the	NULL
DQ3.1	NULL
and	NULL
DQ3.3	NULL
alleles	NULL
.	NULL

These	NULL
peptide	NULL
analogues	NULL
were	NULL
based	NULL
on	NULL
two	NULL
assumptions	NULL
:	NULL
(	NULL
a	NULL
)	NULL
that	NULL
peptide-binding	NULL
pockets	NULL
in	NULL
DQ	NULL
and	NULL
DR	NULL
molecules	NULL
should	NULL
be	NULL
fairly	NULL
homologous	NULL
,	NULL
and	NULL
(	NULL
b	NULL
)	NULL
that	NULL
the	NULL
HSV-2	NULL
peptide	NULL
is	NULL
held	NULL
in	NULL
an	NULL
extended	NULL
conformation	NULL
,	NULL
similar	NULL
to	NULL
the	NULL
extended	NULL
conformation	NULL
of	NULL
the	NULL
HA307-319	NULL
peptide	NULL
in	NULL
DR1	NULL
(	NULL
3	NULL
)	NULL
.	NULL

In	NULL
this	NULL
scenario	NULL
,	NULL
an	NULL
anchor	NULL
residue	NULL
in	NULL
position	NULL
n	NULL
of	NULL
the	NULL
peptide	NULL
should	NULL
fit	NULL
into	NULL
pocket	NULL
one	NULL
,	NULL
and	NULL
residues	NULL
n	NULL
+	NULL
3	NULL
,	NULL
n	NULL
+	NULL
5	NULL
,	NULL
and	NULL
n	NULL
+	NULL
8	NULL
should	NULL
interact	NULL
with	NULL
pockets	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
9	NULL
of	NULL
the	NULL
DQ	NULL
molecule	NULL
,	NULL
respectively	NULL
.	NULL

In	NULL
this	NULL
model	NULL
,	NULL
AspS57	NULL
residues	NULL
may	NULL
influence	NULL
pocket	NULL
9	NULL
of	NULL
the	NULL
DQ3.1	NULL
and	NULL
DQ3.3	NULL
alleles	NULL
by	NULL
forming	NULL
a	NULL
salt	NULL
bridge	NULL
with	NULL
Arg79	NULL
of	NULL
the	NULL
DQa	NULL
chain	NULL
.	NULL

The	NULL
DQ3.2	NULL
molecule	NULL
,	NULL
however	NULL
,	NULL
has	NULL
an	NULL
alanine	NULL
at	NULL
codon	NULL
57	NULL
;	NULL
there	NULL
are	NULL
both	NULL
steric	NULL
and	NULL
charge	NULL
implications	NULL
of	NULL
this	NULL
poly-morphism	NULL
,	NULL
including	NULL
the	NULL
likelihood	NULL
that	NULL
the	NULL
positively	NULL
charged	NULL
Arg79	NULL
may	NULL
interact	NULL
with	NULL
negatively	NULL
charged	NULL
residues	NULL
from	NULL
bound	NULL
peptide	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
Asp57	NULL
salt	NULL
bridge	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
the	NULL
HSV-2	NULL
433-445	NULL
peptide	NULL
is	NULL
consistent	NULL
with	NULL
this	NULL
model	NULL
:	NULL
methionine	NULL
at	NULL
position	NULL
434	NULL
may	NULL
act	NULL
as	NULL
an	NULL
anchor	NULL
residue	NULL
for	NULL
pocket	NULL
1	NULL
,	NULL
and	NULL
aspartic	NULL
acid	NULL
at	NULL
position	NULL
HLA-DQB1	NULL
Codon	NULL
57	NULL
Is	NULL
Critical	NULL
for	NULL
Peptide	NULL
Binding	NULL
and	NULL
Recognition	NULL
pi	NULL
os	NULL
10	NULL
s	NULL
do	NULL
30	NULL
100	NULL
300	NULL
1.000	NULL
stimulation	NULL
index	NULL
none	NULL
425-439	NULL
f	NULL
425-437	NULL
VP16	NULL
peptide	NULL
420-441	NULL
433-445	NULL
0	NULL
10	NULL
0	NULL
20	NULL
0	NULL
ao	NULL
0	NULL
40	NULL
0	NULL
so	NULL
=	NULL
so	NULL
%	NULL
specific	NULL
release	NULL
C	NULL
%	NULL
specific	NULL
release	NULL
at	NULL
DQB1*0302	NULL
DQB1*0302	NULL
433-445	NULL
DQB1*0302	NULL
433-445	NULL
L243	NULL
DQB1*0302	NULL
433-445	NULL
SPVL3	NULL
DQB1*0303	NULL
DQB1*0303	NULL
433-445	NULL
DQB1*0301	NULL
DQB1*0301	NULL
433-445	NULL
DQB1*0603	NULL
433-445	NULL
som	NULL
``	NULL
Cw	NULL
C*	NULL
%	NULL
C	NULL
#	NULL
Figure	NULL
1	NULL
.	NULL

Peptide	NULL
specificity	NULL
and	NULL
restricted	NULL
recognition	NULL
of	NULL
clone	NULL
2A.334	NULL
.	NULL

Proliferative	NULL
response	NULL
of	NULL
clone	NULL
2A.334	NULL
with	NULL
autologous	NULL
PBMC	NULL
as	NULL
APC	NULL
(	NULL
4	NULL
)	NULL
and	NULL
cytotoxic	NULL
activity	NULL
of	NULL
clone	NULL
2A.334	NULL
at	NULL
an	NULL
E/T	NULL
ratio	NULL
of	NULL
20:1	NULL
with	NULL
EBV-transformed	NULL
autologous	NULL
B-LCL	NULL
as	NULL
target	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
or	NULL
homozy-gous	NULL
EBV-transformed	NULL
B-LCL	NULL
with	NULL
different	NULL
DQ	NULL
alleles	NULL
as	NULL
target	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Peptides	NULL
were	NULL
used	NULL
at	NULL
5	NULL
pg/ml	NULL
for	NULL
both	NULL
proliferative	NULL
(	NULL
A	NULL
)	NULL
and	NULL
*'Cr	NULL
release	NULL
assays	NULL
(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

442	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
n	NULL
+	NULL
8	NULL
residue	NULL
,	NULL
may	NULL
interact	NULL
with	NULL
pocket	NULL
9	NULL
.	NULL

To	NULL
test	NULL
this	NULL
hypothesis	NULL
,	NULL
the	NULL
HSV-2	NULL
10A	NULL
peptide	NULL
was	NULL
synthesized	NULL
with	NULL
D-	NULL
>	NULL
A	NULL
substitution	NULL
at	NULL
position	NULL
442	NULL
(	NULL
n	NULL
+	NULL
8	NULL
)	NULL
and	NULL
tested	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
DQ3.1	NULL
,	NULL
DQ3.2	NULL
and	NULL
DQ3.3	NULL
molecules	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
,	NULL
the	NULL
HSV-2	NULL
10A	NULL
peptide	NULL
bound	NULL
to	NULL
both	NULL
DQ3.1	NULL
and	NULL
DQ3.3	NULL
but	NULL
did	NULL
not	NULL
bind	NULL
to	NULL
DQ3.2	NULL
,	NULL
giving	NULL
a	NULL
pattern	NULL
reciprocal	NULL
to	NULL
the	NULL
wild-type	NULL
HSV-2	NULL
433-445	NULL
peptide	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
.	NULL

This	NULL
identifies	NULL
residue	NULL
442	NULL
as	NULL
a	NULL
key	NULL
anchor	NULL
for	NULL
binding	NULL
to	NULL
the	NULL
three	NULL
DQ	NULL
alleles	NULL
,	NULL
complementary	NULL
to	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
polymorphism	NULL
at	NULL
codon	NULL
57	NULL
.	NULL

To	NULL
further	NULL
validate	NULL
the	NULL
role	NULL
of	NULL
M	NULL
at	NULL
position	NULL
434	NULL
and	NULL
D	NULL
1255	NULL
Kwok	NULL
et	NULL
al	NULL
.	NULL

A	NULL
binding	NULL
433-445	NULL
(	NULL
HSV-2	NULL
)	NULL
DQ3.3	NULL
DQ3.2	NULL
DQ3.1	NULL
1	NULL
.	NULL

1	NULL
|	NULL
}	NULL
1	NULL
0	NULL
10	NULL
_	NULL
20	NULL
_	NULL
so	NULL
_	NULL
40	NULL
_	NULL
so	NULL
_	NULL
60	NULL
.	NULL

7o	NULL
fluorescence	NULL
(	NULL
x10	NULL
)	NULL
DQ3.3	NULL
DQ3.2	NULL
DQ3.1	NULL
0	NULL
2	NULL
4	NULL
6	NULL
8	NULL
10	NULL
12	NULL
14	NULL
fluorescence	NULL
(	NULL
x10	NULL
Figure	NULL
2	NULL
.	NULL

Modulation	NULL
of	NULL
HLA-DQ	NULL
binding	NULL
by	NULL
HSV-2	NULL
433-445	NULL
10D-	NULL
>	NULL
10A	NULL
substitution	NULL
.	NULL

Binding	NULL
of	NULL
433-445	NULL
(	NULL
4	NULL
)	NULL
and	NULL
433-445	NULL
10A	NULL
(	NULL
B	NULL
)	NULL
to	NULL
B-LCL	NULL
that	NULL
expressed	NULL
various	NULL
DQw3	NULL
alleles	NULL
.	NULL

at	NULL
position	NULL
442	NULL
as	NULL
anchoring	NULL
residues	NULL
for	NULL
pocket	NULL
1	NULL
and	NULL
pocket	NULL
9	NULL
,	NULL
respectively	NULL
,	NULL
additional	NULL
HSV	NULL
peptide	NULL
analogues	NULL
were	NULL
syn-thesized	NULL
.	NULL

HSV-2	NULL
2L	NULL
and	NULL
HSV-2	NULL
2R	NULL
contain	NULL
an	NULL
L	NULL
and	NULL
an	NULL
R	NULL
substitution	NULL
at	NULL
position	NULL
434	NULL
,	NULL
respectively	NULL
,	NULL
whereas	NULL
HSV-2	NULL
10E	NULL
and	NULL
HSV-2	NULL
10L	NULL
have	NULL
an	NULL
E	NULL
and	NULL
an	NULL
L	NULL
substitution	NULL
at	NULL
position	NULL
442	NULL
,	NULL
respectively	NULL
.	NULL

These	NULL
HSV	NULL
-2	NULL
peptide	NULL
analogues	NULL
were	NULL
tested	NULL
for	NULL
binding	NULL
to	NULL
DQ3.2	NULL
,	NULL
DQ3.3	NULL
,	NULL
and	NULL
DQ3.1	NULL
B-LCLs	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

The	NULL
conservative	NULL
M-L	NULL
substitution	NULL
at	NULL
position	NULL
434	NULL
(	NULL
HSV-2	NULL
2L	NULL
)	NULL
had	NULL
little	NULL
influence	NULL
on	NULL
binding	NULL
to	NULL
DQ3.2	NULL
compared	NULL
with	NULL
the	NULL
native	NULL
HSV-2	NULL
433-445	NULL
peptide	NULL
,	NULL
whereas	NULL
there	NULL
was	NULL
a	NULL
substantial	NULL
decrease	NULL
in	NULL
binding	NULL
with	NULL
the	NULL
more	NULL
drastic	NULL
M-R	NULL
substitution	NULL
in	NULL
the	NULL
HSV-2	NULL
2R	NULL
peptide	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
a	NULL
conservative	NULL
E	NULL
substitution	NULL
at	NULL
position	NULL
442	NULL
(	NULL
HSV-2	NULL
10E	NULL
)	NULL
bound	NULL
to	NULL
DQ3.2	NULL
much	NULL
better	NULL
than	NULL
HSV-2	NULL
10L	NULL
.	NULL

As	NULL
with	NULL
the	NULL
HSV-2	NULL
10A	NULL
peptide	NULL
,	NULL
which	NULL
failed	NULL
to	NULL
bind	NULL
to	NULL
DQ3.2	NULL
but	NULL
was	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
DQ3.1	NULL
and	NULL
DQ3.3	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
)	NULL
,	NULL
the	NULL
HSV-2	NULL
10L	NULL
peptide	NULL
also	NULL
bound	NULL
to	NULL
Brief	NULL
Definitive	NULL
Report	NULL
A	NULL
DQ3.2	NULL
HSV-2	NULL
2L	NULL
HSV-2	NULL
2R	NULL
HSV-2	NULL
10E	NULL
HSV-2	NULL
10L	NULL
l	NULL
R	NULL
L	NULL
1	NULL
l	NULL
:	NULL
a	NULL
l	NULL
0	NULL
10	NULL
_	NULL
20	NULL
_	NULL
30	NULL
_	NULL
40	NULL
_	NULL
50	NULL
_	NULL
60	NULL
fluorescence	NULL
(	NULL
x10	NULL
~	NULL
)	NULL
B	NULL
DQ3.3	NULL
HSVv-2	NULL
108	NULL
|	NULL
HSV-2	NULL
10L	NULL
;	NULL
.	NULL

.	NULL

l	NULL
R	NULL
R	NULL
.	NULL

1	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
fluorescence	NULL
(	NULL
x10	NULL
%	NULL
)	NULL
1	NULL
C	NULL
DQ3.1	NULL
HSV-2	NULL
10€	NULL
HSV-2	NULL
10L	NULL
l	NULL
.	NULL

i	NULL
R	NULL
1	NULL
:	NULL
I	NULL
a	NULL
I	NULL
I	NULL
.	NULL

t	NULL
0	NULL
4	NULL
0	NULL
2	NULL
30°	NULL
40005000600	NULL
70	NULL
8	NULL
fluorescence	NULL
(	NULL
x10	NULL
%	NULL
)	NULL
DQ3.3	NULL
and	NULL
DQ3.1	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
substantiate	NULL
the	NULL
assumption	NULL
that	NULL
in	NULL
this	NULL
peptide	NULL
,	NULL
residue	NULL
434	NULL
is	NULL
the	NULL
pocket	NULL
1	NULL
anchor	NULL
and	NULL
that	NULL
a	NULL
negatively	NULL
charged	NULL
residue	NULL
at	NULL
the	NULL
n	NULL
+	NULL
8	NULL
position	NULL
is	NULL
critical	NULL
for	NULL
allele-specific	NULL
binding	NULL
to	NULL
DQ3.2	NULL
.	NULL

Presumably	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
Asp57	NULL
salt	NULL
bridge	NULL
,	NULL
the	NULL
negatively	NULL
charged	NULL
residue	NULL
at	NULL
position	NULL
n	NULL
+	NULL
8	NULL
of	NULL
the	NULL
peptide	NULL
can	NULL
interact	NULL
with	NULL
the	NULL
accessible	NULL
Arg79	NULL
of	NULL
the	NULL
DQa	NULL
chain	NULL
,	NULL
and	NULL
,	NULL
conversely	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
salt	NULL
bridge	NULL
,	NULL
a	NULL
negatively	NULL
charged	NULL
residue	NULL
at	NULL
the	NULL
n	NULL
+	NULL
8	NULL
position	NULL
appears	NULL
to	NULL
be	NULL
unfavorable	NULL
for	NULL
peptide	NULL
binding	NULL
.	NULL

These	NULL
HSV	NULL
-2	NULL
peptide	NULL
analogues	NULL
were	NULL
then	NULL
tested	NULL
for	NULL
recognition	NULL
by	NULL
T	NULL
cell	NULL
clone	NULL
2A.334	NULL
.	NULL

As	NULL
anticipated	NULL
from	NULL
the	NULL
binding	NULL
studies	NULL
,	NULL
HSV-2	NULL
2L	NULL
and	NULL
native	NULL
433-445	NULL
peptide	NULL
stimulated	NULL
clone	NULL
2A.334	NULL
with	NULL
DQ3.2	NULL
B-LCL	NULL
as	NULL
APC	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
HSV-2	NULL
2R	NULL
peptide	NULL
,	NULL
however	NULL
,	NULL
was	NULL
presented	NULL
only	NULL
at	NULL
much	NULL
higher	NULL
peptide	NULL
concentration	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
C	NULL
)	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
observation	NULL
that	NULL
this	NULL
peptide	NULL
bound	NULL
less	NULL
efficiently	NULL
to	NULL
DQ3.2	NULL
.	NULL

Peptide	NULL
analogues	NULL
with	NULL
substitutions	NULL
at	NULL
position	NULL
442	NULL
were	NULL
also	NULL
analyzed	NULL
.	NULL

Peptide	NULL
HSV-2	NULL
10E	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
D	NULL
)	NULL
was	NULL
presented	NULL
by	NULL
DQ3.2	NULL
,	NULL
like	NULL
the	NULL
native	NULL
HSV-2	NULL
433-445	NULL
peptide	NULL
.	NULL

The	NULL
HSV-2	NULL
10A	NULL
and	NULL
HSV-2	NULL
10L	NULL
ana-logues	NULL
,	NULL
however	NULL
,	NULL
showed	NULL
no	NULL
cytolytic	NULL
recognition	NULL
by	NULL
clone	NULL
2A.334	NULL
on	NULL
DQ3.2	NULL
target	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
E	NULL
and	NULL
F	NULL
)	NULL
.	NULL

These	NULL
results	NULL
correlated	NULL
with	NULL
the	NULL
lack	NULL
of	NULL
binding	NULL
of	NULL
these	NULL
peptides	NULL
to	NULL
DQ3.2	NULL
B-LCL	NULL
.	NULL

However	NULL
,	NULL
clone	NULL
2A.334	NULL
was	NULL
able	NULL
to	NULL
recognize	NULL
the	NULL
HSV-2	NULL
10A	NULL
and	NULL
HSV-2	NULL
10L	NULL
peptides	NULL
when	NULL
they	NULL
were	NULL
presented	NULL
by	NULL
DQ3.3	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
E	NULL
and	NULL
F	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
both	NULL
HSV-2	NULL
peptides	NULL
with	NULL
a	NULL
negatively	NULL
charged	NULL
residue	NULL
at	NULL
position	NULL
442	NULL
complexed	NULL
with	NULL
DQ3.2	NULL
and	NULL
also	NULL
HSV-2	NULL
peptides	NULL
with	NULL
an	NULL
aliphatic	NULL
side	NULL
chain	NULL
residue	NULL
at	NULL
position	NULL
442	NULL
complexed	NULL
with	NULL
DQ3.3	NULL
were	NULL
recognized	NULL
by	NULL
the	NULL
clone	NULL
2A.334	NULL
,	NULL
indicating	NULL
the	NULL
generation	NULL
of	NULL
similar	NULL
MHC-peptide	NULL
complexes	NULL
by	NULL
the	NULL
structural	NULL
complementation	NULL
of	NULL
residue	NULL
442	NULL
and	NULL
codon	NULL
57	NULL
.	NULL

Interestingly	NULL
,	NULL
though	NULL
the	NULL
HSV-2	NULL
10A	NULL
and	NULL
10L	NULL
peptides	NULL
bound	NULL
to	NULL
DQ3.1	NULL
,	NULL
these	NULL
DQ-HSV-2	NULL
complexes	NULL
were	NULL
not	NULL
recognized	NULL
by	NULL
the	NULL
2A.334	NULL
clone	NULL
.	NULL

This	NULL
indicates	NULL
modulation	NULL
of	NULL
T	NULL
cell	NULL
recognition	NULL
by	NULL
the	NULL
additional	NULL
polymorphic	NULL
sites	NULL
,	NULL
which	NULL
are	NULL
unique	NULL
to	NULL
DQ3.1	NULL
,	NULL
and	NULL
two	NULL
alternative	NULL
explanations	NULL
are	NULL
feasible	NULL
.	NULL

Polymorphic	NULL
residues	NULL
13	NULL
and	NULL
26	NULL
of	NULL
the	NULL
DQ3.1	NULL
molecule	NULL
are	NULL
likely	NULL
to	NULL
lie	NULL
in	NULL
the	NULL
floor	NULL
of	NULL
the	NULL
peptide-binding	NULL
groove	NULL
,	NULL
such	NULL
that	NULL
the	NULL
HSV-2	NULL
peptides	NULL
could	NULL
be	NULL
presented	NULL
by	NULL
the	NULL
DQ3.1	NULL
molecule	NULL
in	NULL
a	NULL
different	NULL
conformation	NULL
because	NULL
of	NULL
these	NULL
changes	NULL
.	NULL

Similar	NULL
observations	NULL
have	NULL
been	NULL
reported	NULL
by	NULL
others	NULL
for	NULL
DR4-restricted	NULL
clones	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
DQ3.1	NULL
molecule	NULL
has	NULL
a	NULL
bulky	NULL
residue	NULL
at	NULL
position	NULL
45	NULL
,	NULL
that	NULL
,	NULL
though	NULL
located	NULL
outisde	NULL
the	NULL
peptide-binding	NULL
groove	NULL
and	NULL
the	NULL
a	NULL
helix	NULL
,	NULL
may	NULL
interfere	NULL
directly	NULL
with	NULL
interaction	NULL
with	NULL
the	NULL
TCR	NULL
.	NULL

This	NULL
alternative	NULL
is	NULL
consistent	NULL
with	NULL
previous	NULL
observations	NULL
that	NULL
residue	NULL
45	NULL
is	NULL
an	NULL
immu-nodominanat	NULL
mAb-binding	NULL
epitope	NULL
on	NULL
the	NULL
DQ3.1	NULL
molecule	NULL
(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
.	NULL

In	NULL
sum	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
a	NULL
critical	NULL
role	NULL
for	NULL
the	NULL
DQB	NULL
polymorphism	NULL
at	NULL
codon	NULL
57	NULL
as	NULL
a	NULL
structural	NULL
and	NULL
functional	NULL
Figure	NULL
3	NULL
.	NULL

-	NULL
Binding	NULL
of	NULL
HSV	NULL
433-445	NULL
position	NULL
2	NULL
and	NULL
10	NULL
analogues	NULL
to	NULL
(	NULL
4	NULL
)	NULL
DQ3.2	NULL
,	NULL
(	NULL
B	NULL
)	NULL
DQ3.3	NULL
,	NULL
and	NULL
(	NULL
C	NULL
)	NULL
DQ3.1	NULL
.	NULL

1256	NULL
HLA-DQB1	NULL
Codon	NULL
57	NULL
Is	NULL
Critical	NULL
for	NULL
Peptide	NULL
Binding	NULL
and	NULL
Recognition	NULL
A	NULL
B	NULL
C	NULL
80	NULL
©	NULL
meve	NULL
a	NULL
*	NULL
heve	NULL
ar	NULL
a	NULL
]	NULL
pos.2	NULL
sol	NULL
a	NULL
|pas.2	NULL
/	NULL
w	NULL
60	NULL
w	NULL
a	NULL
4°	NULL
J	NULL
+	NULL
2	NULL
Lao	NULL
}	NULL
E3	NULL
o	NULL
o	NULL
p	NULL
30	NULL
}	NULL
P	NULL
5	NULL
40	NULL
I§	NULL
30	NULL
|-	NULL
's	NULL
'	NULL
©	NULL
3	NULL
&	NULL
20	NULL
|-	NULL
L	NULL
#	NULL
20	NULL
-	NULL
t	NULL
1	NULL
x	NULL
»	NULL
20	NULL
xe	NULL
®	NULL
u	NULL
[	NULL
+	NULL
10	NULL
10	NULL
!	NULL

78	NULL
lw	NULL
a	NULL
z	NULL
:	NULL
A.	NULL
Bas	NULL
:	NULL
P	NULL
Merit	NULL
.	NULL

boos	NULL
0.05	NULL
0.5	NULL
5	NULL
tous	NULL
0.05	NULL
0.5	NULL
ce	NULL
M.ous	NULL
0.05	NULL
0.5	NULL
5	NULL
peptide	NULL
concentration	NULL
(	NULL
ug/ml	NULL
!	NULL
)	NULL

peptide	NULL
concentration	NULL
(	NULL
g/m	NULL
!	NULL
)	NULL

peptide	NULL
concentration	NULL
(	NULL
ug/m	NULL
!	NULL
)	NULL

D	NULL
E	NULL
F	NULL
70	NULL
80	NULL
heve	NULL
oE	NULL
HSV2	NULL
10A	NULL
°	NULL
rev	NULL
tol	NULL
bass	NULL
60	NULL
|-	NULL
_	NULL
»	NULL
|oas	NULL
a	NULL
vases	NULL
so	NULL
|	NULL
«	NULL
O|	NULL
=-	NULL
.	NULL

w	NULL
60	NULL
}	NULL
a	NULL
a	NULL
50|	NULL
*	NULL
I	NULL
'T	NULL
€	NULL
,	NULL
``	NULL
€	NULL
C	NULL
a0|	NULL
o	NULL
40	NULL
}	NULL
#	NULL
0	NULL
o	NULL
<	NULL
»	NULL
€	NULL
&	NULL
®	NULL
30	NULL
}	NULL
a	NULL
§	NULL
``	NULL
|	NULL
ES	NULL
;	NULL
®	NULL
a	NULL
.	NULL

/	NULL
o.	NULL
a.	NULL
t	NULL
a	NULL
p	NULL
t	NULL
a	NULL
20	NULL
se	NULL
20	NULL
+-	NULL
,	NULL
a	NULL
®	NULL
20	NULL
}	NULL
x	NULL
t	NULL
10	NULL
F	NULL
r	NULL
0	NULL
10	NULL
a	NULL
=~	NULL
DQ3.1	NULL
«	NULL
(	NULL
mn	NULL
oa	NULL
oer	NULL
gim	NULL
frc	NULL
bass	NULL
DQ3.1	NULL
oue	NULL
forme	NULL
...	NULL
R	NULL
Das	NULL
.	NULL

1	NULL
b.oos	NULL
0.05	NULL
0.5	NULL
§	NULL
24°	NULL
boos	NULL
0.05	NULL
0.5	NULL
g	NULL
0032	NULL
1.005	NULL
0.05	NULL
0.5	NULL
g	NULL
0032	NULL
peptide	NULL
concentration	NULL
(	NULL
g/m	NULL
!	NULL
)	NULL

peptide	NULL
concentration	NULL
(	NULL
g/m	NULL
!	NULL
)	NULL

peptide	NULL
concentration	NULL
(	NULL
ug/ml	NULL
)	NULL
Figure	NULL
4	NULL
.	NULL

-	NULL
Modulation	NULL
of	NULL
T	NULL
cell	NULL
recognition	NULL
by	NULL
HSV	NULL
433-445	NULL
analogues	NULL
.	NULL

``	NULL
Cr	NULL
release	NULL
assays	NULL
with	NULL
clone	NULL
24.334	NULL
on	NULL
B-LCL	NULL
that	NULL
expressed	NULL
different	NULL
DQw3	NULL
alleles	NULL
and	NULL
loaded	NULL
with	NULL
(	NULL
4	NULL
)	NULL
HSV-2	NULL
433-445	NULL
,	NULL
(	NULL
B	NULL
)	NULL
HSV-2	NULL
2L	NULL
,	NULL
(	NULL
C	NULL
)	NULL
HSV-2	NULL
2R	NULL
,	NULL
(	NULL
D	NULL
)	NULL
HSV-2	NULL
2E	NULL
,	NULL
(	NULL
E	NULL
)	NULL
HSV-2	NULL
10A	NULL
,	NULL
or	NULL
(	NULL
F	NULL
)	NULL
HSV-2	NULL
10L	NULL
were	NULL
used	NULL
as	NULL
targets	NULL
.	NULL

determinant	NULL
of	NULL
peptide-specific	NULL
recognition	NULL
.	NULL

This	NULL
polymor-	NULL
__	NULL
peptides	NULL
with	NULL
negatively	NULL
charged	NULL
anchor	NULL
residues	NULL
interact-phism	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
a	NULL
major	NULL
contributor	NULL
to	NULL
allelic	NULL
specific-	NULL
_	NULL
ing	NULL
with	NULL
the	NULL
class	NULL
II	NULL
pocket	NULL
.	NULL

ity	NULL
,	NULL
with	NULL
preferential	NULL
binding	NULL
of	NULL
Asp-negative	NULL
alleles	NULL
to	NULL
We	NULL
thank	NULL
Drs	NULL
.	NULL

R.	NULL
Burke	NULL
and	NULL
Dr.	NULL
M.	NULL
Tigges	NULL
for	NULL
providing	NULL
peptides	NULL
,	NULL
and	NULL
Holly	NULL
Chase	NULL
for	NULL
preparation	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Insititutes	NULL
of	NULL
Health	NULL
grants	NULL
DK-02319	NULL
,	NULL
DK-40964	NULL
(	NULL
W.W.	NULL
Kwok	NULL
)	NULL
and	NULL
Al-34616	NULL
(	NULL
D.M	NULL
.	NULL

Koelle	NULL
}	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
Dr.	NULL
William	NULL
W.	NULL
Kwok	NULL
,	NULL
Virginia	NULL
Mason	NULL
Research	NULL
Center	NULL
,	NULL
1000	NULL
Seneca	NULL
Street	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98101	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
17	NULL
July	NULL
1995	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
8	NULL
November	NULL
1995	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Engelhard	NULL
,	NULL
V.H	NULL
.	NULL

1994	NULL
.	NULL

Structure	NULL
of	NULL
peptides	NULL
associated	NULL
with	NULL
4	NULL
.	NULL

Brown	NULL
J.H	NULL
.	NULL

,	NULL
TS	NULL
.	NULL

Jardetzky	NULL
,	NULL
J.C.	NULL
Gorga	NULL
,	NULL
L.J	NULL
.	NULL

Stern	NULL
,	NULL
RG	NULL
.	NULL

Ur-class	NULL
I	NULL
and	NULL
class	NULL
II	NULL
MHC	NULL
molecules	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12	NULL
:	NULL
ban	NULL
,	NULL
J.L	NULL
.	NULL

Strominger	NULL
,	NULL
and	NULL
D.C.	NULL
Wiley	NULL
.	NULL

1993	NULL
.	NULL

Three-dimen-181-207	NULL
.	NULL

sional	NULL
structure	NULL
of	NULL
the	NULL
human	NULL
class	NULL
II	NULL
histocompatibility	NULL
anti	NULL
2	NULL
.	NULL

Madden	NULL
,	NULL
D.R	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
three-dimensional	NULL
structure	NULL
of	NULL
pep-	NULL
gen	NULL
HLA-DR	NULL
1	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

364:33-39.	NULL
tide-MHC	NULL
complexes	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

13:587-622	NULL
.	NULL

5	NULL
.	NULL

Hammer	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
Valsasnini	NULL
,	NULL
K.	NULL
Tolba	NULL
,	NULL
D.	NULL
Bolin	NULL
,	NULL
J.	NULL
Higelin	NULL
,	NULL
B	NULL
.	NULL

3	NULL
.	NULL

Stem	NULL
,	NULL
LJ	NULL
.	NULL

,	NULL
J.H	NULL
.	NULL

Brown	NULL
,	NULL
TS	NULL
.	NULL

Jardetzky	NULL
,	NULL
J.C.	NULL
Gorga	NULL
,	NULL
R.G	NULL
.	NULL

Ur-	NULL
Takacs	NULL
,	NULL
and	NULL
F.	NULL
Sinigaglia	NULL
.	NULL

1993	NULL
.	NULL

Promiscuous	NULL
and	NULL
allele-spe-ban	NULL
,	NULL
J.L	NULL
.	NULL

Strominger	NULL
,	NULL
and	NULL
D.C.	NULL
Wiley	NULL
,	NULL
1994	NULL
.	NULL

Crystal	NULL
structure	NULL
cific	NULL
anchors	NULL
in	NULL
HLA-DR-binding	NULL
peptides	NULL
.	NULL

Cell	NULL
.	NULL

74:197-203.	NULL
of	NULL
the	NULL
human	NULL
class	NULL
II	NULL
MHC	NULL
protein	NULL
HLA-DR1	NULL
complexed	NULL
6	NULL
.	NULL

Chicz	NULL
,	NULL
R.M	NULL
.	NULL

,	NULL
R.G	NULL
.	NULL

Urban	NULL
,	NULL
J.C.	NULL
Gorga	NULL
,	NULL
D.A.A	NULL
.	NULL

Vignali	NULL
,	NULL
W.S	NULL
.	NULL

with	NULL
an	NULL
influenza	NULL
virus	NULL
peptide	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

368:215-221	NULL
.	NULL

Lane	NULL
,	NULL
and	NULL
J.L	NULL
.	NULL

Strominger	NULL
.	NULL

1993	NULL
.	NULL

Specificity	NULL
and	NULL
promiscuity	NULL
1257	NULL
-	NULL
Kwok	NULL
etal	NULL
.	NULL

-	NULL
Brief	NULL
Definitive	NULL
Report	NULL
9	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13.	NULL
among	NULL
naturally	NULL
processed	NULL
peptides	NULL
bound	NULL
to	NULL
HLA-DR	NULL
alleles	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:27-47.	NULL
.	NULL

Marshall	NULL
,	NULL
KW	NULL
.	NULL

,	NULL
A.F	NULL
.	NULL

Liu	NULL
,	NULL
J.	NULL
Canales	NULL
,	NULL
B.	NULL
Perahia	NULL
,	NULL
B.	NULL
Jorgensen	NULL
,	NULL
RD	NULL
.	NULL

Gantzos	NULL
,	NULL
B.	NULL
Aguilar	NULL
,	NULL
B.	NULL
Devaux	NULL
,	NULL
and	NULL
J.B.	NULL
Rothbard	NULL
.	NULL

1994	NULL
.	NULL

Role	NULL
of	NULL
the	NULL
polymorphic	NULL
residues	NULL
in	NULL
HLA-DR	NULL
molecules	NULL
in	NULL
allele-specific	NULL
binding	NULL
of	NULL
peptide	NULL
ligands	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

152:4946-4957.	NULL
.	NULL

Sidney	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
Oseroff	NULL
,	NULL
M.	NULL
del	NULL
Guercio	NULL
,	NULL
S.	NULL
Southwood	NULL
,	NULL
J.I	NULL
.	NULL

Krieger	NULL
,	NULL
G.Y	NULL
.	NULL

Ishioka	NULL
,	NULL
K.	NULL
Sakaguchi	NULL
,	NULL
E.	NULL
Appella	NULL
,	NULL
and	NULL
A.	NULL
Sette	NULL
.	NULL

1994	NULL
.	NULL

Definition	NULL
of	NULL
a	NULL
-specific	NULL
binding	NULL
motif	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

152:4516-4525	NULL
,	NULL
Verreck	NULL
,	NULL
FA.W	NULL
.	NULL

,	NULL
A.	NULL
van	NULL
de	NULL
Poel	NULL
,	NULL
A.	NULL
Termijtelen	NULL
,	NULL
R.	NULL
Amons	NULL
,	NULL
J.	NULL
Drijfhout	NULL
,	NULL
and	NULL
F.	NULL
Koning	NULL
.	NULL

1994	NULL
.	NULL

Identification	NULL
of	NULL
an	NULL
HLA-DQ2	NULL
peptide	NULL
binding	NULL
motif	NULL
and	NULL
HLA-DPw3-bound	NULL
self-peptide	NULL
by	NULL
pool	NULL
sequencing	NULL
.	NULL

Eur	NULL
J.	NULL
Immunol	NULL
.	NULL

24:375-379	NULL
.	NULL

Chicz	NULL
,	NULL
R.M	NULL
.	NULL

,	NULL
W.S	NULL
.	NULL

Lane	NULL
,	NULL
R.A.	NULL
Robinson	NULL
,	NULL
M.	NULL
Trucco	NULL
,	NULL
J.L	NULL
.	NULL

Strominger	NULL
,	NULL
and	NULL
J.C.	NULL
Gorga	NULL
.	NULL

1994	NULL
.	NULL

Self-peptides	NULL
bound	NULL
to	NULL
the	NULL
type	NULL
I	NULL
diabetes	NULL
associated	NULL
class	NULL
II	NULL
MHC	NULL
molecules	NULL
HLA-DQ1	NULL
and	NULL
HLA-DQ8	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

6:1639-1649	NULL
.	NULL

Nepom	NULL
,	NULL
G.T	NULL
.	NULL

1994	NULL
.	NULL

Class	NULL
II	NULL
antigens	NULL
and	NULL
disease	NULL
susceptibil-ity	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Med	NULL
.	NULL

46:17-25	NULL
.	NULL

Todd	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
J.I	NULL
.	NULL

Bell	NULL
,	NULL
and	NULL
H.O	NULL
.	NULL

McDevitt	NULL
.	NULL

1987	NULL
.	NULL

HLA-DQRB	NULL
gene	NULL
contributes	NULL
to	NULL
susceptibility	NULL
and	NULL
resistance	NULL
to	NULL
insulin-dependent	NULL
diabetes	NULL
mellitus	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

329:599-604	NULL
.	NULL

Wucherpfenning	NULL
,	NULL
K.W	NULL
.	NULL

,	NULL
and	NULL
J.L	NULL
.	NULL

Strominger	NULL
.	NULL

1995	NULL
.	NULL

Selective	NULL
binding	NULL
of	NULL
self	NULL
peptides	NULL
to	NULL
disease-associated	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
molecules	NULL
:	NULL
a	NULL
mechanism	NULL
for	NULL
MHC-linked	NULL
susceptibility	NULL
to	NULL
human	NULL
autoimmune	NULL
diseases	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

1258	NULL
14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

Med	NULL
.	NULL

181:1597-1601	NULL
.	NULL

Koelle	NULL
,	NULL
D.M	NULL
.	NULL

,	NULL
H.	NULL
Abbo	NULL
,	NULL
A.	NULL
Peck	NULL
,	NULL
K.	NULL
Ziegweid	NULL
,	NULL
and	NULL
L.	NULL
Co-rey	NULL
.	NULL

1994	NULL
.	NULL

Direct	NULL
recovery	NULL
of	NULL
HSV-specific	NULL
T	NULL
lymphocyte	NULL
clones	NULL
from	NULL
recurrent	NULL
HSV-2	NULL
lesions	NULL
.	NULL

J.	NULL
Infect	NULL
Dis	NULL
.	NULL

169:956-961	NULL
.	NULL

Moretta	NULL
,	NULL
A.	NULL
,	NULL
G.	NULL
Pantaleo	NULL
,	NULL
L.	NULL
Moretta	NULL
,	NULL
J.-C.	NULL
Cerottini	NULL
,	NULL
and	NULL
M.C	NULL
.	NULL

Mingari	NULL
.	NULL

1983	NULL
.	NULL

Direct	NULL
demonstration	NULL
of	NULL
the	NULL
clonogenic	NULL
potential	NULL
of	NULL
every	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cell	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

157:743-754	NULL
.	NULL

Koelle	NULL
,	NULL
D.M	NULL
.	NULL

,	NULL
L.	NULL
Corey	NULL
,	NULL
RL	NULL
.	NULL

Burke	NULL
,	NULL
R.J.	NULL
Eisenberg	NULL
,	NULL
G.H	NULL
.	NULL

Cohen	NULL
,	NULL
R.	NULL
Pichyangkura	NULL
,	NULL
and	NULL
S.J	NULL
.	NULL

Triezenberg	NULL
.	NULL

1994	NULL
.	NULL

Antigenic	NULL
specificity	NULL
of	NULL
human	NULL
CD4*	NULL
T	NULL
cell	NULL
clones	NULL
recovered	NULL
from	NULL
recurrent	NULL
genital	NULL
HSV-2	NULL
lesions	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:2803-2810	NULL
.	NULL

Kwok	NULL
,	NULL
W.	NULL
,	NULL
G.T	NULL
.	NULL

Nepom	NULL
,	NULL
and	NULL
F.C	NULL
.	NULL

Raymond	NULL
.	NULL

1995	NULL
.	NULL

HLA-DQ	NULL
polymorphisms	NULL
are	NULL
highly	NULL
selective	NULL
for	NULL
peptide	NULL
binding	NULL
interactions	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

155:2468-2476	NULL
.	NULL

Fu	NULL
,	NULL
X.	NULL
,	NULL
C.P	NULL
.	NULL

Bono	NULL
,	NULL
S.L	NULL
.	NULL

Woulfe	NULL
,	NULL
C.	NULL
Swearingen	NULL
,	NULL
N.L	NULL
.	NULL

Sum-mers	NULL
,	NULL
F.	NULL
Sinigaglia	NULL
,	NULL
A.	NULL
Sette	NULL
,	NULL
B.D	NULL
.	NULL

Schwartz	NULL
,	NULL
and	NULL
R.W	NULL
.	NULL

Karr	NULL
.	NULL

1995	NULL
.	NULL

Pocket	NULL
4	NULL
of	NULL
the	NULL
HLA-DR	NULL
(	NULL
«	NULL
,	NULL
B1*0401	NULL
)	NULL
molecule	NULL
is	NULL
a	NULL
major	NULL
determinant	NULL
of	NULL
T	NULL
cell	NULL
recognition	NULL
of	NULL
peptide	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:915-926	NULL
.	NULL

Kwok	NULL
,	NULL
W.W.	NULL
,	NULL
C.	NULL
Lotshaw	NULL
,	NULL
E.C	NULL
.	NULL

Milner	NULL
,	NULL
N.	NULL
Knitter-Jack	NULL
,	NULL
and	NULL
G.T	NULL
.	NULL

Nepom	NULL
.	NULL

1989	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
the	NULL
HLA-DQ3.2	NULL
IDDM	NULL
susceptibility	NULL
gene	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:1027-1030	NULL
.	NULL

Kwok	NULL
,	NULL
W.W.	NULL
,	NULL
E.	NULL
Mickelson	NULL
,	NULL
S.	NULL
Masewicz	NULL
,	NULL
E.C.B	NULL
.	NULL

Milner	NULL
,	NULL
J.	NULL
Hansen	NULL
,	NULL
and	NULL
G.T	NULL
.	NULL

Nepom	NULL
.	NULL

1990	NULL
.	NULL

Polymorphic	NULL
DQa	NULL
and	NULL
DQB	NULL
interactions	NULL
dictate	NULL
HLA	NULL
class	NULL
II	NULL
determinants	NULL
of	NULL
allo-recognition	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

171:85-95	NULL
.	NULL

HLA-DQBA1	NULL
Codon	NULL
57	NULL
Is	NULL
Critical	NULL
for	NULL
Peptide	NULL
Binding	NULL
and	NULL
Recognition	NULL

